Find therapies in clinical trials near you

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Study on the Effectiveness of Infliximab, Ustekinumab, and Vedolizumab for Patients with Resistant Crohn's Disease

Study on the Effectiveness of Infliximab, Ustekinumab, and Vedolizumab for Patients with Resistant Crohn's Disease

Study on Vedolizumab and Ustekinumab for Patients with Crohn's Disease and Ulcerative Colitis

Study on Vedolizumab and Ustekinumab for Patients with Crohn's Disease and Ulcerative Colitis

Study Comparing Ustekinumab, Infliximab, and Combination Therapy for Patients with Moderate to Severe Ulcerative Colitis

Study Comparing Ustekinumab, Infliximab, and Combination Therapy for Patients with Moderate to Severe Ulcerative Colitis

Study on Transmural Healing in Patients with Moderate to Severe Crohn's Disease Using Upadacitinib and Drug Combination

Study on Transmural Healing in Patients with Moderate to Severe Crohn's Disease Using Upadacitinib and Drug Combination

Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

Study on Preventing Crohn's Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk

Study on Preventing Crohn's Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk

Reducing Toxicity of Dual PD‑1 and CTLA‑4 Checkpoint Therapy in Pleural Mesothelioma Patients with Ustekinumab (anti‑p40)

Reducing Toxicity of Dual PD‑1 and CTLA‑4 Checkpoint Therapy in Pleural Mesothelioma Patients with Ustekinumab (anti‑p40)

A study comparing vedolizumab, filgotinib, ustekinumab, and infliximab to maintain remission in patients with ulcerative colitis

A study comparing vedolizumab, filgotinib, ustekinumab, and infliximab to maintain remission in patients with ulcerative colitis

Study of ustekinumab, adalimumab, and baricitinib for patients with folliculitis decalvans that is difficult to treat

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn's Disease